Special report: maintenance therapy in advanced non-small-cell lung cancer.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D054598:Blue Cross Blue Shield Insurance Plans; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D017277:Drug Approval; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D010043:Outcome and Process Assessment, Health Care; D017671:Platinum Compounds / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D017671:Platinum Compounds